Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Final Data Unveiled, Vertex Will Move Its CF Combo Into Pivotal Trials In 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite controversies about incorrectly reported data and allegations of incomplete data, Vertex has demonstrated lung function benefit for a combination of Kalydeco and VX-809 in Phase II and will move the combination into Phase III trials early next year.

You may also be interested in...



Uncertain About HCV, Vertex Doubles Down On CF, Looks To Sell Off Pipeline Assets

As it nears a crucial inflexion point for its hepatitis C business, Vertex shifts focus to building on its strong early start in cystic fibrosis. The Boston-area firm plans to out-license its mid-stage candidates for autoimmune disease and influenza A.

Analysts Miffed By Vertex’s Lack Of Transparency With CF Combo Data

Vertex Pharmaceuticals presented top-line data for its drug combination in cystic fibrosis, but analysts are wondering why the company was not forthcoming about the full data set.

Vertex’s CF Therapy Combination Trial Yields Promising Lung-Function Data

Interim data from a Phase II study investigating Kalydeco with VX-809 showed statistically significant FEV-1 improvement across dosing groups; the company hopes to start a pivotal Phase III program for the combo in late 2012 or early 2013.

Topics

Related Companies

UsernamePublicRestriction

Register

PS073354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel